NCT05157971View on ClinicalTrials.gov

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

February 7, 2026

Study Completion Date

February 7, 2026

Conditions
B Acute Lymphoblastic LeukemiaPh-Like Acute Lymphoblastic Leukemia
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given SC, IV or IT

DRUG

Daunorubicin Hydrochloride

Given IV

DRUG

Mercaptopurine

Given PO

DRUG

Methotrexate

Given IT

DRUG

Pegaspargase

Given IM or IV

DRUG

Prednisone

Given PO

DRUG

Venetoclax

Given PO

DRUG

Vincristine Sulfate

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER